Pilot Feasibility Trial of a Supportive Care Digital Application for Patients with Advanced Nonsmall Cell Lung Cancer.

Boulanger, Mary C; Lo, Stephen B; Centracchio, Joely A; Jewett, Brianna; Freese, Madison; Holtze, Mia; Jacobs, Jamie M; Petrillo, Laura A et al. · J Palliat Med · 2025

rct · Level II

Where this comes from

Abstract

<b><i>Background:</i></b> Patients with advanced nonsmall cell lung cancer (NSCLC) experience burdensome symptoms, psychological distress, and poor quality of life (QOL). <b><i>Objective:</i></b> We developed and pilot-tested a digital health application ("THRIVE"), consisting of six modules designed to improve patients' symptom management and coping with NSCLC. <b><i>Design:</i></b> Randomized pilot feasibility trial. <b><i>Setting/Subjects:</i></b> Eligible patients included adults within 12 weeks of an advanced NSCLC diagnosis receiving care at a participating institution in the United States. <b><i>Measurements:</i></b> Participants completed baseline and 12-week assessments of QOL (Functional Assessment of Cancer Therapy-Lung), physical symptoms (MD Anderson Symptom Inventory; MDASI), psychological distress (Hospital Anxiety and Depression Scale), and coping (Brief COPE). The primary outcome was study feasibility, defined as ≥65% of approached patients consenting to participate; ≥70% of intervention participants completing ≥4 of 6 app modules; and ≥70% of the sample completing the 12-week assessments. We used the System Usability Scale (SUS) to assess intervention acceptability. <b><i>Results:</i></b> Of 232 patients approached, 135 (58.2%) provided consent, and 120 (51.7%) were randomized (Age<sub>mean</sub> = 67.90 years, 61.7% female, 90.8% White). Among intervention participants, 70.5% (43/61) completed ≥4 modules, with 77.3% reporting above-average SUS usability ratings for THRIVE. Ninety-four (78.3%) participants completed the 12-week assessments. <b><i>Conclusions:</i></b> Although the enrollment rate was lower than anticipated, patients with advanced NSCLC who received THRIVE met the feasibility criterion for app completion and reported high acceptability. These results support conducting a follow-up efficacy trial of THRIVE for improving patients' QOL, physical symptoms, and other psychosocial outcomes.

Medical subject headings